SLL, or small lymphocytic lymphoma, is a slow-growing cancer of the immune system. It develops when a type of white blood cell called a B-lymphocyte grows out of control and accumulates primarily in the lymph nodes. SLL is essentially the same disease as chronic lymphocytic leukemia (CLL), with one key distinction: in SLL, the cancerous cells collect mainly in the lymph nodes and spleen rather than flooding the bloodstream.
How SLL Relates to CLL
SLL and CLL have been considered the same disease for nearly two decades. The cancer cells look identical under a microscope, carry the same protein markers on their surface, and behave in similar ways. The difference comes down to where those cells show up. In CLL, large numbers of abnormal lymphocytes circulate in the blood. In SLL, patients present with swollen lymph nodes and sometimes an enlarged spleen, but their blood counts remain relatively normal. Because the diseases are so closely related, doctors group them together as CLL/SLL and treat them using the same guidelines.
What Happens at the Cell Level
SLL originates from a specific subset of B cells that carry a surface protein called CD5. These CD5-positive B cells exist in healthy people and can even form small clusters of identical cells in young adults, which may represent a very early step on the path toward disease. In SLL, these cells lose their normal checks on growth. Genes that would ordinarily slow proliferation or trigger programmed cell death become less active. At the same time, the cells don’t die on schedule the way healthy immune cells do. The result is a gradual buildup of long-lived, dysfunctional lymphocytes that crowd out healthy tissue in the lymph nodes.
Common Symptoms
Early-stage SLL often causes no symptoms at all, and many people are diagnosed incidentally during routine bloodwork or a physical exam. When symptoms do appear, the most common is painless swelling of the lymph nodes, typically felt as a lump under the skin in the neck, armpit, or groin.
Some people develop what doctors call “B symptoms,” a specific cluster of systemic signs that indicate the disease is becoming more active:
- Drenching night sweats that soak through clothing or bedding
- Unexplained weight loss of 10% or more of body weight within six months
- Persistent fever lasting more than two weeks without an infection
- Fatigue significant enough to interfere with daily activities
Other possible symptoms include pain in the chest, abdomen, or bones, itchy skin, and a persistent cough. Because SLL grows slowly, these symptoms tend to develop gradually over months or years rather than appearing suddenly.
How SLL Is Diagnosed
A definitive SLL diagnosis requires a lymph node biopsy. Doctors remove part or all of an enlarged lymph node and examine the cells using a technique called flow cytometry, which identifies specific proteins on the cell surface. SLL cells display a characteristic pattern: they are positive for CD5, CD19, and CD23, while showing unusually low levels of CD20 and a protein called surface immunoglobulin. This combination helps distinguish SLL from other lymphomas that can look similar, particularly mantle cell lymphoma, which is positive for CD5 but negative for CD23.
A newer scoring system adds markers like CD200 and the ratio of CD19 to CD20 to improve diagnostic accuracy, especially in borderline cases that don’t fit the classic pattern neatly.
Genetic Factors That Affect Outlook
Not all SLL behaves the same way, and genetic testing plays a major role in predicting how aggressive the disease will be. The most significant finding is a deletion on chromosome 17p or a mutation in the TP53 gene. Patients with either of these abnormalities tend to have lower response rates to standard treatments and more aggressive disease overall. The International Prognostic Index for CLL formally classifies anyone with TP53 abnormalities as high-risk.
Other chromosomal changes, like deletions on chromosomes 11 or 13, also factor into prognosis but carry different levels of concern. Genetic testing at diagnosis helps guide decisions about when and how to treat.
Survival Rates
Because SLL and CLL are managed as the same disease, survival statistics are reported together. For patients with low-risk scores (0 to 1 on the prognostic index), the five-year survival rate is approximately 90%, and the ten-year survival rate is about 86%. These numbers drop significantly for high-risk disease: patients scoring 7 to 10 on the index have a five-year survival rate of roughly 23%.
These figures reflect averages across large groups of patients. Individual outcomes vary widely depending on genetics, age at diagnosis, and how the disease responds to treatment. Many people with low-risk SLL live for decades with minimal intervention.
Watch and Wait: The Most Common Early Approach
One of the most surprising aspects of SLL for newly diagnosed patients is that treatment often doesn’t start right away. Because the disease progresses slowly, doctors frequently recommend a strategy called “watch and wait” (or active surveillance), where you have regular checkups and blood tests but no treatment until the disease meets specific thresholds.
Treatment typically begins when one or more of the following occurs:
- Lymph nodes grow to 10 centimeters or larger
- The spleen extends 6 centimeters or more below the rib cage
- Hemoglobin or platelet counts drop consistently below 100, not explained by other causes
- White blood cell counts double in less than six months
- B symptoms (fever, night sweats, significant weight loss) persist for more than two weeks without infection
- Fatigue becomes severe enough to prevent normal daily activities
There is no single magic number that triggers treatment. The decision is based on the overall picture of how the disease is progressing and how it affects your quality of life. Some patients remain on watch and wait for years, while others need treatment within months of diagnosis.
Richter Transformation: A Rare but Serious Risk
In a small percentage of cases, SLL transforms into a faster-growing, more aggressive lymphoma. This is called Richter transformation, and it occurs in an estimated 2 to 9% of CLL/SLL patients. Most commonly, it transforms into diffuse large B cell lymphoma, though a very small fraction (around 0.4%) develop Hodgkin lymphoma instead.
Richter transformation tends to announce itself with a sudden change in symptoms: rapid swelling of lymph nodes (often in the abdomen), worsening night sweats, fever, and unexplained weight loss. Another warning sign is when one group of lymph nodes grows much faster than others, or when one area responds to treatment while another continues to worsen. About half of patients with Richter transformation develop significant anemia, and a similar proportion have low platelet counts. If you have an established SLL diagnosis and notice a sudden escalation in symptoms after a period of stability, that warrants prompt evaluation.